Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study.

Maio, MicheleShapira-Frommer, RonnieYap, Timothy A.Ciuleanu, TudorGomez, HenryHill, AndrewLugowska, IwonaOzyilkan, OzgurVera, KarinaIm, Seock-AhKryzhanivska, AnnaLysenko, SerhiiSchenker, MichaelStemmer, Salomon M.Saraf, SanatanCristescu, RazvanJin, FanGozmen, AlexanderQuintela-Fandino, Miguel2022-08-252022-08-2520210008-5472http://hdl.handle.net/11727/7418enginfo:eu-repo/semantics/closedAccessOlaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study.Conference Object8113000680263501334